Cargando…

Potassium-Competitive Acid Blockers (P-CABs): Are They Finally Ready for Prime Time in Acid-Related Disease?

The need for new acid suppressing agents with improved pharmacology and superior antisecretory effects to address unmet clinical needs in acid-related disorders has been evident for over a decade. Recent new antisecretory drugs (IR-omeprazole and MR-dexlansoprazole) only provide a small incremental...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hunt, Richard H, Scarpignato, Carmelo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2015
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4816037/ https://www.ncbi.nlm.nih.gov/pubmed/26513137 http://dx.doi.org/10.1038/ctg.2015.39

Ejemplares similares

Role of potassium-competitive acid blockers in eradication of Helicobacter pylori infection
por: Kim, Tae Ho
Publicado: (2023)

Pathophysiology of Potassium-competitive Acid Blocker–refractory Gastroesophageal Reflux and the Potential of Potassium-competitive Acid Blocker Test
por: Masaoka, Tatsuhiro, et al.
Publicado: (2018)

Potassium-competitive acid blockers and gastroesophageal reflux disease
por: Leowattana, Wattana, et al.
Publicado: (2022)

Protonated Form: The Potent Form of Potassium-Competitive Acid Blockers
por: Luo, Hua-Jun, et al.
Publicado: (2014)

The Effect of Food on the Pharmacokinetics of the Potassium‐Competitive Acid Blocker Vonoprazan
por: Mulford, Darcy J., et al.
Publicado: (2021)

Potassium-competitive acid blockers - are they the next generation of proton pump inhibitors?
por: Rawla, Prashanth, et al.
Publicado: (2018)

Gastric polyps' regression after potassium‐competitive acid blocker cessation
por: Iwamuro, Masaya, et al.
Publicado: (2022)

REBOA: is it ready for prime time?
por: Doucet, Jay, et al.
Publicado: (2017)

Role of Acid Suppression in Acid-related Diseases: Proton Pump Inhibitor and Potassium-competitive Acid Blocker
por: Mori, Hideki, et al.
Publicado: (2019)

Potent Potassium-competitive Acid Blockers: A New Era for the Treatment of Acid-related Diseases
por: Oshima, Tadayuki, et al.
Publicado: (2018)

Hypercontractile esophagus responsive to potassium-competitive acid blockers: a case report
por: Shao, Yuyang, et al.
Publicado: (2022)

Severe Hypomagnesemia Associated with the Long-term Use of the Potassium-competitive Acid Blocker Vonoprazan
por: Okamoto, Masaru, et al.
Publicado: (2021)

JP‐1366: A novel and potent potassium‐competitive acid blocker that is effective in the treatment of acid‐related diseases
por: Ku, Jin Mo, et al.
Publicado: (2023)

Usefulness of vonoprazan, a potassium ion-competitive acid blocker, for primary eradication of Helicobacter pylori
por: Yamada, Shinya, et al.
Publicado: (2016)

Noninvasive Electrocardiographic Mapping: Are We Ready for Prime Time?
por: Aryana, Arash, et al.
Publicado: (2015)

New Advances in Cardiorenal Syndrome—Ready for Prime Time?
por: Pliquett, Rainer U.
Publicado: (2022)

Potassium-competitive acid blockers, a new therapeutic class, and their role in acid-related diseases: a narrative review
por: Domingues, Gerson, et al.
Publicado: (2022)

Novel Potassium-Competitive Acid Blocker, Tegoprazan, Protects Against Colitis by Improving Gut Barrier Function
por: Son, Mijeong, et al.
Publicado: (2022)

Distribution- and Metabolism-Based Drug Discovery: A Potassium-Competitive Acid Blocker as a Proof of Concept
por: Wang, Ming-Shu, et al.
Publicado: (2022)

Endoscopic ultrasound guided gallbladder drainage - is it ready for prime time?
por: Boregowda, Umesha, et al.
Publicado: (2018)

Role of vitamin C in diabetic ketoacidosis: Is it ready for prime time?
por: Casillas, Sebastian, et al.
Publicado: (2018)

Antibody testing for coronavirus disease 2019: not ready for prime time
por: Duong, Yen T, et al.
Publicado: (2020)

The omega-3 index in Alzheimer's disease: Ready for prime time?
por: Yassine, Hussein N
Publicado: (2022)

Pediatric Post-TB Lung Disease: Ready for Prime Time?
por: Masekela, Refiloe, et al.
Publicado: (2023)

Randomised clinical trial: tegoprazan, a novel potassium‐competitive acid blocker, or lansoprazole in the treatment of gastric ulcer
por: Cho, Yu Kyung, et al.
Publicado: (2020)

Evaluation of pharmacokinetic interactions between amoxicillin, clarithromycin, and the potassium-competitive acid blocker YH4808 in healthy subjects
por: Lee, Woo Yul, et al.
Publicado: (2020)

Is a Potassium-Competitive Acid Blocker Truly Superior to Proton Pump Inhibitors in Terms of Helicobacter pylori Eradication?
por: Sue, Soichiro, et al.
Publicado: (2021)

Diagnostic errors: moving beyond ‘no respect’ and getting ready for prime time
por: Singh, Hardeep
Publicado: (2013)

Endoscopic ultrasound-guided pancreatic duct drainage: Ready for the prime time?
por: Giovannini, Marc
Publicado: (2017)

Randomised clinical trial: vonoprazan, a novel potassium‐competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis
por: Ashida, K., et al.
Publicado: (2015)

Treatment strategies for reflux esophagitis including a potassium‐competitive acid blocker: A cost‐effectiveness analysis in Japan
por: Habu, Yasuki, et al.
Publicado: (2021)

Efficacy of Image Enhanced Endoscopy for Colorectal Polyps: Are we Ready for Prime Time?
por: Neumann, Helmut, et al.
Publicado: (2017)

Is Buprenorphine-Naloxone Ready for Prime Time in the Treatment of Opioid Addiction in Managed Care?
por: Curtiss, Frederic R.
Publicado: (2008)

Genomic arrays for the identification of high-risk chronic lymphocytic leukemia: ready for prime time?
por: Cuneo, Antonio, et al.
Publicado: (2021)

Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date
por: Sugano, Kentaro
Publicado: (2018)

Randomised phase 3 trial: tegoprazan, a novel potassium‐competitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis
por: Lee, Kwang Jae, et al.
Publicado: (2019)

Efficacy of Seven-Day Potassium-Competitive Acid Blocker-Based First-Line Helicobacter Pylori Eradication Therapy Administered with Bismuth
por: Kim, Ji Yeon, et al.
Publicado: (2021)

Keverprazan, a novel potassium‐competitive acid blocker: Multiple oral doses safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy subjects
por: Zhou, Sufeng, et al.
Publicado: (2023)

A comparison of efficacy and safety of potassium‐competitive acid blocker and proton pump inhibitor in gastric acid‐related diseases: A systematic review and meta‐analysis
por: Simadibrata, Daniel Martin, et al.
Publicado: (2022)

Are We Right on Target? Is Comprehensive Genomic Profiling Ready for Prime Time in Resource-Constrained Settings?
por: Ghosh, Joydeep, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_33iqddj4q1n05519c5bf3f1idu